Cellectis (NASDAQ:CLLS) Share Price Passes Below Fifty Day Moving Average – Time to Sell?

Shares of Cellectis S.A. (NASDAQ:CLLS) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $3.70 and traded as low as $3.59. Cellectis shares last traded at $3.63, with a volume of 29,099 shares.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CLLS. Jefferies Financial Group began coverage on Cellectis in a report on Tuesday, February 17th. They set a “buy” rating and a $7.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a report on Monday, April 20th. Finally, Citizens Jmp restated a “market outperform” rating and set a $8.00 price objective on shares of Cellectis in a report on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $6.75.

Cellectis Trading Down 1.1%

The stock has a market capitalization of $364.23 million, a price-to-earnings ratio of -5.42 and a beta of 2.94. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.52 and a current ratio of 1.52. The firm has a fifty day moving average of $3.70 and a 200-day moving average of $4.03.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.08. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.The firm had revenue of $7.55 million during the quarter, compared to the consensus estimate of $11.04 million.

Institutional Trading of Cellectis

Several large investors have recently added to or reduced their stakes in the stock. Lido Advisors LLC acquired a new stake in Cellectis in the 1st quarter valued at $32,000. Marshall Wace LLP increased its holdings in Cellectis by 1,610.3% in the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after purchasing an additional 168,038 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Cellectis in the 4th quarter valued at $15,385,000. Global Retirement Partners LLC acquired a new stake in Cellectis in the 4th quarter valued at $34,000. Finally, Millennium Management LLC increased its holdings in Cellectis by 61.9% in the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 22,080 shares in the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.